Mcrae Capital Management Inc. Sells 515 Shares of Johnson & Johnson $JNJ

Mcrae Capital Management Inc. lessened its position in Johnson & Johnson (NYSE:JNJ) by 3.9% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 12,548 shares of the company’s stock after selling 515 shares during the quarter. Mcrae Capital Management Inc.’s holdings in Johnson & Johnson were worth $1,917,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in JNJ. Nuveen LLC bought a new stake in shares of Johnson & Johnson in the first quarter valued at approximately $1,369,188,000. Pacer Advisors Inc. increased its position in Johnson & Johnson by 1,382.0% during the first quarter. Pacer Advisors Inc. now owns 3,030,084 shares of the company’s stock worth $502,509,000 after acquiring an additional 2,825,626 shares during the period. Assenagon Asset Management S.A. raised its stake in Johnson & Johnson by 159.6% during the 2nd quarter. Assenagon Asset Management S.A. now owns 4,159,260 shares of the company’s stock valued at $635,327,000 after purchasing an additional 2,557,388 shares during the last quarter. Kingstone Capital Partners Texas LLC bought a new stake in Johnson & Johnson in the 2nd quarter valued at $401,420,000. Finally, Dimensional Fund Advisors LP grew its position in Johnson & Johnson by 14.4% in the 1st quarter. Dimensional Fund Advisors LP now owns 16,903,105 shares of the company’s stock worth $2,803,042,000 after purchasing an additional 2,129,612 shares during the last quarter. 69.55% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the business’s stock in a transaction dated Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the sale, the executive vice president directly owned 178,013 shares of the company’s stock, valued at $31,652,491.53. The trade was a 24.08% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Stock Up 0.5%

NYSE:JNJ opened at $186.92 on Friday. The company has a quick ratio of 0.80, a current ratio of 1.07 and a debt-to-equity ratio of 0.50. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $194.48. The stock’s fifty day simple moving average is $184.06 and its 200-day simple moving average is $168.42. The firm has a market capitalization of $450.33 billion, a P/E ratio of 18.04, a P/E/G ratio of 2.19 and a beta of 0.38.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. The company had revenue of $24.02 billion for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. Equities research analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 9th. Stockholders of record on Tuesday, November 25th will be given a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.8%. The ex-dividend date of this dividend is Tuesday, November 25th. Johnson & Johnson’s payout ratio is currently 50.19%.

Analyst Ratings Changes

A number of analysts have commented on the company. Royal Bank Of Canada reiterated an “outperform” rating and issued a $209.00 price objective on shares of Johnson & Johnson in a research report on Friday, October 10th. Wall Street Zen raised Johnson & Johnson from a “hold” rating to a “buy” rating in a research note on Saturday, September 13th. Raymond James Financial upped their price objective on shares of Johnson & Johnson from $174.00 to $209.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 15th. UBS Group lifted their target price on shares of Johnson & Johnson from $190.00 to $214.00 and gave the company a “buy” rating in a research note on Tuesday, October 14th. Finally, Argus set a $210.00 price target on Johnson & Johnson in a report on Wednesday, October 15th. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have issued a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $199.05.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.